One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Centering Patient Voices Through Community Engagement in Cardiovascular Research.
Powell-Wiley, Tiffany M. MD, MPH
doi : 10.1161/CIRCULATIONAHA.122.061112
Volume 147(2) pgs. 105-186,e4-e31 January 10, 2023
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Kang, Jeehoon MD ,*; Park, Kyung Woo MD ,*; Lee, Huijin MD; Hwang, Doyeon MD; Yang, Han-Mo MD; Rha, Seung-Woon MD; Bae, Jang-Whan MD; Lee, Nam Ho MD; Hur, Seung-Ho MD; Han, Jung-Kyu MD; Shin, Eun-Seok MD; Koo, Bon-Kwon MD; Kim, Hyo-Soo MD
doi : 10.1161/CIRCULATIONAHA.122.062770
Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial.
Long-Term P2Y12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention.
Capodanno, Davide MD, PhD; Angiolillo, Dominick J. MD, PhD
Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
Paluch, Amanda E. PhD; Bajpai, Shivangi MS; Ballin, Marcel MSc; Bassett, David R. PhD; Buford, Thomas W. PhD; Carnethon, Mercedes R. PhD; Chernofsky, Ariel PhD, MS; Dooley, Erin E. PhD; Ekelund, Ulf PhD; Evenson, Kelly R. PhD; Galuska, Deborah A. PhD; Jefferis, Barbara J. PhD; Kong, Lingsong MS; Kraus, William E. MD; Larson, Martin G. PhD; Lee, I-Min ScD; Matthews, Charles E. PhD; Newton, Robert L. Jr PhD; Nordstrom, Anna MD, PhD; Nordstrom, Peter MD, PhD; Palta, Priya PhD; Patel, Alpa V. PhD; Pettee Gabriel, Kelley PhD; Pieper, Carl F. PhD; Pompeii, Lisa PhD; Rees-Punia, Erika PhD; Spartano, Nicole L. PhD; Vasan, Ramachandran S. MD; Whincup, Peter H. PhD; Yang, Shengping PhD; Fulton, Janet E. PhD; for the Steps for Health Collaborative
doi : 10.1161/CIRCULATIONAHA.122.061288
Taking fewer than the widely promoted "10 000 steps per day" has recently been associated with lower risk of all-cause mortality. The relationship of steps and cardiovascular disease (CVD) risk remains poorly described. A meta-analysis examining the dose-response relationship between steps per day and CVD can help inform clinical and public health guidelines.Â
Heterogeneity in the Association Between the Presence of Coronary Artery Calcium and Cardiovascular Events: A Machine-Learning Approach in the MESA Study.
Inoue, Kosuke MD, PhD; Seeman, Teresa E. PhD; Horwich, Tamara MD, MS; Budoff, Matthew J. MD; Watson, Karol E. MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.062626
Coronary artery calcium (CAC) has been widely recognized as an important predictor of cardiovascular disease (CVD). Given the finite resources, it is important to identify individuals who would receive the most benefit from detecting positive CAC by screening.
Cardiac Troponin I-Interacting Kinase Affects Cardiomyocyte S-Phase Activity but Not Cardiomyocyte Proliferation.
Reuter, Sean P. BS; Soonpaa, Mark H. PhD; Field, Dorothy MS; Simpson, Ed PhD; Rubart-von der Lohe, Michael MD; Lee, Han Kyu PhD; Sridhar, Arthi MS; Ware, Stephanie M. MD, PhD; Green, Nick BS; Li, Xiaochun PhD; Ofner, Susan MS; Marchuk, Douglas A. PhD; Wollert, Kai C. MD; Field, Loren J. PhD
doi : 10.1161/CIRCULATIONAHA.122.061130
Identifying genetic variants that affect the level of cell cycle reentry and establishing the degree of cell cycle progression in those variants could help guide development of therapeutic interventions aimed at effecting cardiac regeneration.
A Tedious Journey: Cardiomyocyte Proliferation Requires More Than S-Phase Entry and Loss of Polyploidization.
Ding, Dong PhD; Braun, Thomas MD, PhD
Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.
Gao, Pan PhD; Cao, Mengying BS; Jiang, Xueli MD, PhD; Wang, Xiaolin BS; Zhang, Guoping BS; Tang, Xinru BS; Yang, Chunjie BS; Komuro, Issei MD, PhD; Ge, Junbo MD, PhD; Li, Liliang MD, PhD; Zou, Yunzeng MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.059304
Diabetic heart dysfunction is a common complication of diabetes. Cell death is a core event that leads to diabetic heart dysfunction. However, the time sequence of cell death pathways and the precise time to intervene of particular cell death type remain largely unknown in the diabetic heart.Â
What Is the Truth Behind Abnormal ECG Changes?.
Yang, Zhangli MD; Zhang, Chuan-Hai MD; Li, Xuanxuan MD
Increasing Mononuclear Diploid Cardiomyocytes by Loss of E2F Transcription Factor 7/8 Fails to Improve Cardiac Regeneration After Infarct.
Yu, Zhe PhD ,*; Zhang, Lunfeng PhD ,*; Cattaneo, Paola PhD; Guimaraes-Camboa, Nuno PhD; Fang, Xi PhD; Gu, Yusu MS; Peterson, Kirk L. MD; Bogomolovas, Julius PhD; Cuitino, Cecilia PhD; Leone, Gustavo W. PhD; Chen, Ju PhD; Evans, Sylvia M. PhD
Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association.
Chow, Sheryl L. PharmD, FAHA, Chair; Bozkurt, Biykem MD, PhD, FAHA, Vice Chair; Baker, William L. PharmD, FAHA; Bleske, Barry E. PharmD; Breathett, Khadijah MD, MS, FAHA; Fonarow, Gregg C. MD, FAHA; Greenberg, Barry MD, FAHA; Khazanie, Prateeti MD, MPH; Leclerc, Jacinthe RN, PhD, FAHA; Morris, Alanna A. MD, MSc; Reza, Nosheen MD; Yancy, Clyde W. MD, FAHA; on behalf of the American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing
doi : 10.1161/CIR.0000000000001110
AB Complementary and alternative medicines (CAM) are commonly used across the world by diverse populations and ethnicities but remain largely unregulated. Although many CAM agents are purported to be efficacious and safe by the public, clinical evidence supporting the use of CAM in heart failure remains limited and controversial.
Correction to: Substrate Ablation by Multivein, Multiballoon Coronary Venous Ethanol for Refractory Ventricular Tachycardia in Structural Heart Disease.
